Nevertheless, MGMT inhibitors appear to be mandatory in MGMT-expressing tumors for DIX-dependent cancer therapeutic approaches in which TMZ or dacarbazine are applied to induce cancer cell immunogenicity. This evidence concerns the gene MGMT and cancer.